On February 1, 2025, the WID®-easy Test was presented in the ORF program “Bewusst Gesund”. The report shows how this innovative epigenetic test revolutionizes the early detection of uterine cancer and can spare affected women invasive procedures.

Uterine cancer is the most common gynecological cancer – even more common than cervical cancer. This not only affects older women, but also younger women. A research team led by Prof. Dr. Martin Widschwendter has made significant progress in detecting carcinomas of the uterus earlier and more reliably.

The ORF report particularly emphasizes the WID®-easy Test. Using an epigenetic analysis, the test can identify malignant changes at an early stage. This enables timely, targeted treatment and can spare affected women invasive procedures.

Another test method for the early detection of cervical cancer is currently under development. Initial results show that the test can identify 69% of women who could develop cervical cancer or a preliminary stage within the next one to six years by analyzing a simple smear test.

The WID®-easy Test represents a significant advance in gynecology, as it not only makes the diagnosis more precise, but also reduces the risk of unnecessary treatment. The test is already available in Austria, Switzerland and the UK and offers a new option for early cancer detection.

You can find the complete ORF report here: ORF Mediathek